● Recruiting

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Condition: Barrett's Esophagus Without Dysplasia · Barrett Oesophagitis With Dysplasia · Esophageal Adenocarcinoma · Sponsor: University Medical Center Groningen

PhasePhase 2

Planned participants25

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

This description comes directly from the study's public registry record.

Talk to the study team

Wouter B Nagengast, Prof. dr. · +31(0)503615755 · w.b.nagengast@umcg.nl

Always discuss trial participation with your own doctor first.

Locations (1)

University Medical Center Groningen

Groningen, Provincie Groningen, Netherlands

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05745857